Pharma
Reflecting on our campaign to increase volunteer diversity
NIHR BioResource for Translational Research writes...As our 12-week campaign with Egality Health and eight community-based health advocacy organisations has come to a close, we’re reflecting on our successes and sharing some key learnings going forward. We also heard from some of our co...
Redundancy: A Golden-Ticket Opportunity (face to face or Virtual Event)
If you are in the Life Sciences, Pharma, Medical Devices or Health Tech industries, and whether you're currently facing potential redundancy, actively seeking a new opportunity, or have previously encountered redundancy and wish to share your experiences while extending a helping hand t...
Milner Therapeutics Institute to house world-class functional genomics laboratory, in new partnership with AstraZeneca and the Medical Research Council
The University of Cambridge announces a new partnership with AstraZeneca and the Medical Research Council (MRC) that will establish a new state-of-the-art functional genomics laboratory at the Milner Therapeutics Institute. ...
Are Free Energy Perturbation (FEP) methods suitable for your project?
Free Energy Perturbation (FEP) methods are a fast-evolving area of drug discovery, and Cresset Discovery’s dedicated team of expert modelers are establishing a rapidly growing portfolio of successfully completed FEP projects. There are a number of key data requirements that are necessar...
IPFL expands printing possibilities with new multi-material polyjet printer
Multi material production 3D Printing and prototyping IPFL, experts in plastic machining, fabrication and 3D printing, has begun running the latest J850 Polyjet 3D printer from Stratasys. The machine will support the company’s compilation of 3D printing technologies and expan...
Unleashing the potential of Micro 3D Printing with the BMF PµSL System
IPFL is at the forefront of micro 3D printing innovation with the BMF PµSL system, offering unparalleled precision in manufacturing microscale components. Ideal for aerospace, medical, and electronics industries, this advanced technology enables the creation of highly detailed parts pre...
Streamlining the design of PROTACs® and PROTAC linkers
Register here - Streamlining the design of PROTACs® and PROTAC linkers (cresset-group.com) ...
3 Steps for cell & gene therapy medical affairs teams to provide strategic value
A phrase often recited within the pharmaceutical and biotechnology industries in recent years is that medical affairs is the third strategic pillar of success, along with R&D and commercial. Ongoing advancements in the cell and gene therapy sector have further highlighted the critic...
The Paradigm Shift: Navigating the emergence of value-based contracts for future gene therapies
Value-based contracting (VBC) has been difficult to execute in the pharmaceutical arena, especially in the gene therapy space. This has been driven by several factors, including the lack of long-term data, the imbalance of upside and downside risk between manufacturers and payers, and d...
A longitudinal perspective on innovation
There is growing interest in the innovation process in the biopharmaceutical industry, with particular public scrutiny around the composition of research and development (R&D) spending and the role of intellectual property. This process is commonly characterized as involving a mixtu...